Log in

Seelos Therapeutics Stock Price, Forecast & Analysis (NASDAQ:SEEL)

$0.86
+0.08 (+10.26 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$0.75
Now: $0.86
$0.89
50-Day Range
$0.72
MA: $0.89
$0.98
52-Week Range
$0.72
Now: $0.86
$10.50
Volume271,500 shs
Average Volume177,141 shs
Market Capitalization$23.18 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SEEL
CUSIPN/A
CIKN/A
Phone646-998-6475

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.76 million
Book Value$0.38 per share

Profitability

Net Income$-9,240,000.00

Miscellaneous

EmployeesN/A
Market Cap$23.18 million
Next Earnings Date2/6/2020 (Estimated)
OptionableNot Optionable

Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.


Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Seelos Therapeutics.

What price target have analysts set for SEEL?

3 Wall Street analysts have issued 1 year target prices for Seelos Therapeutics' stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Seelos Therapeutics' share price to reach $5.33 in the next year. This suggests a possible upside of 520.2% from the stock's current price. View Analyst Price Targets for Seelos Therapeutics.

What is the consensus analysts' recommendation for Seelos Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seelos Therapeutics.

Has Seelos Therapeutics been receiving favorable news coverage?

News stories about SEEL stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Seelos Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Seelos Therapeutics.

Who are some of Seelos Therapeutics' key competitors?

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include TrovaGene (TROV), Crispr Therapeutics (CRSP), Sesen Bio (SESN), Amneal Pharmaceuticals (AMRX), Canopy Growth (CGC), Galena Biopharma (SLS), ABIOMED (ABMD), AcelRx Pharmaceuticals (ACRX), ADMA Biologics (ADMA) and Aileron Therapeutics (ALRN).

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the folowing people:
  • Dr. Raj Mehra Ph.D., Chairman, CEO, Pres & Interim CFO (Age 59)

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.36%).

Which institutional investors are buying Seelos Therapeutics stock?

SEEL stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $0.86.

How big of a company is Seelos Therapeutics?

Seelos Therapeutics has a market capitalization of $23.18 million and generates $5.76 million in revenue each year. View Additional Information About Seelos Therapeutics.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is http://www.seelostx.com/.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-998-6475 or via email at [email protected]


MarketBeat Community Rating for Seelos Therapeutics (NASDAQ SEEL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  44
MarketBeat's community ratings are surveys of what our community members think about Seelos Therapeutics and other stocks. Vote "Outperform" if you believe SEEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SEEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: Trading Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel